MeiraGTx Holdings PLC (MGTX)
Stock Price:
$12.94 USD
0.02 (0.15%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
483.48M |
| Revenue (ttm) |
17.21M |
| Net Income (ttm) |
-57.04M |
| Shares Out |
37.36M |
| EPS (ttm) |
-1.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$12.94 |
| Previous Close |
$12.92 |
| Change ($) |
0.02 |
| Change (%) |
0.15% |
| Day's Open |
13.09 |
| Day's Range |
12.45 - 13.17 |
| Day's Volume |
36,339 |
| 52-Week Range |
8.82 - 22.32 |
More Stats
| Market Cap |
483.48M |
| Enterprise Value |
309.36M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.36M |
| Float |
25.01M |
| EPS (basic) |
-1.54 |
| EPS (diluted) |
-1.58 |
| FCF / Share |
-2.15 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
390,590 |
| Short Ratio |
2.91 |
| Short % of Float |
1.56% |
| Beta |
1.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
28.10 |
| PB Ratio |
2.82 |
| Revenue |
17.21M |
| Operating Income |
-74.46M |
| Net Income |
-57.04M |
| Free Cash Flow |
-79.37M |
| Net Cash |
174.12M |
| Net Cash / Share |
4.66 |
| Gross Margin |
77.24% |
| Operating Margin |
-432.71% |
| Profit Margin |
n/a |
| FCF Margin |
-461.20% |
| ROA |
-13.16% |
| ROE |
-37.73% |
| ROIC |
-87.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$33.33*
(157.57% upside)
Low
20.0
Current: $12.94
High
45.0
Target: 33.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -71.56 | -78.10 | -31.68 | -20.06 |
| Net Income | -54.75 | -82.87 | -31.04 | -19.49 |
| Shares Outstanding | 33.16 | 18.95 | 8.57 | 31.10 |
| Earnings Per Share | -1.65 | -4.47 | -3.72 | -0.63 |
| Operating Cash Flow | 20.04 | -58.89 | -18.06 | -14.37 |
| Capital Expenditures | -8.98 | -11.26 | -10.54 | -2.59 |
| Free Cash Flow | 11.06 | -70.15 | -28.59 | -16.96 |
| Cash & Equivalents | 227 | 68.20 | 8.67 | 17.92 |
| Total Debt | 23.18 | 0.03 | 1.51 | 0.01 |
| Net Cash / Debt | 204 | 68.17 | 7.16 | 17.91 |
| Assets | 324 | 96.89 | 25.85 | 22.55 |
| Liabilities | 133 | 15.84 | 21.88 | 6.86 |
| Book Value | 191 | 81.06 | -47.37 | -17.14 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
MeiraGTx Holdings PLC |
| Country |
United States |
| Employees |
168 |
| CEO |
Alexandria Forbes |
Stock Information
| Ticker Symbol |
MGTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MGTX |
Description
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.